Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

ImmunoGen Inc (NASDAQ:IMGN)

6.55
Delayed Data
As of Sep 22
 +0.05 / +0.77%
Today’s Change
1.51
Today|||52-Week Range
8.84
+221.08%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Biotechnology
MARKET CAP
$735.0M

Company Description

ImmunoGen, Inc. is a biotechnology company, which develops novel anticancer therapeutics using its antibody-drug conjugate technology. Its product candidates include Mirvetuximab Soravtansine, Coltuximab ravtansine and Kadcyla . The company was founded in March 1981 and is headquartered in Waltham, MA.

Contact Information

ImmunoGen, Inc.
830 Winter Street
Waltham Massachusetts 02451-1477
P:(781) 895-0600
Investor Relations:

Employees

Shareholders

Other institutional53.74%
Mutual fund holders34.10%
Individual stakeholders3.12%

Top Executives

Mark J. EnyedyPresident, Chief Executive Officer & Director
David B. JohnstonChief Financial Officer & Executive Vice President
Richard J. GregoryChief Scientific Officer & Executive VP
Anna BerkenblitChief Medical Officer & Vice President
Thomas RyllVice President-Technical Operations